Use of Antihyperglycemic Medications Among US People with Limited English Proficiency.

Background: Language barriers can impact pharmaceutical disease management leading to potential health disparities among limited English proficiency (LEP) people with diabetes mellitus (DM) in the United States (US).

Objective: To assess the use of antihyperglycemic medications and estimate their impact on glycemic control by LEP status.

Design: Cross-sectional design.

CD19-CAR T-cell therapy induces deep tissue depletion of B cells.

Objectives: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy can induce long-term drug-free remission in patients with autoimmune diseases (AIDs). The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo.

Methods: Sequential ultrasound-guided inguinal lymph node biopsies were performed at baseline and after CD19-CAR T-cell therapy in patients with AIDs.

Tuning Colloidal Gel Properties: The Influence of Central and Noncentral Forces.

Colloidal gels, ubiquitous in industrial applications, can undergo reversible solid-to-liquid transitions. Recent work demonstrates that adding surface roughness to primary particles enhances the toughness and influences the self-healing properties of colloidal gels. In the present work, we first use colloidal probe atomic force microscopy (CP-AFM) to assess the quantitative changes in adhesive and frictional forces between thermoresponsive particles as a function of their roughness.

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model.

Immune-checkpoint-inhibitors (ICI) target key regulators of the immune system expressed by cancer cells that mask those from recognition by the immune system. They have improved the outcome for patients with various cancer types, such as melanoma. ICI-based therapy is frequently accompanied by immune-related adverse side effects (IRAEs).